E.P. and C.L. contributed equally to this work.
Full-Length Original Research
Fractalkine/CX3CL1 modulates GABAA currents in human temporal lobe epilepsy
Article first published online: 13 SEP 2013
Wiley Periodicals, Inc. © 2013 International League Against Epilepsy
Volume 54, Issue 10, pages 1834–1844, October 2013
How to Cite
Epilepsia, 54(10):1834–1844, 2013
- Issue published online: 1 OCT 2013
- Article first published online: 13 SEP 2013
- Manuscript Accepted: 30 JUL 2013
- PRIN 2009
- Ministero della Sanità Antidoping
- Cenci Bolognetti
- National Epilepsy Fund. Grant Numbers: NEF 05-11, NEF 09-05
Data S1. Methods.
Figure S1. CX3CL1 does not influence GABA current rundown in oocytes co-injected with human α1β2γ2 GABAA subunits and CX3CR1 cDNAs.
Figure S2. Distribution of CX3CR1 immunoreactivity in the hippocampus of control and MTLE patients with hippocampal sclerosis.
Figure S3. Evaluation of CX3CR1 immunoreactivity in control hippocampus and in hippocampal sclerosis.
Figure S4. CX3CR1 immunoreactivity in FCD.
Figure S5. CX3CR1 expression in hippocampal tissues of MTLE patients.
Table S1. Clinical characteristics and neurophysiologic findings of patients.
Table S2. CX3CR1 expression in glial cells in control hippocampus and in hippocampal MTLE patients.
Table S3. GABAergic characteristics and rundown in control nonepileptic patients.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.